Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT06046040
First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 3 times
Summary
This early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and attack prostate cancer cells while also resisting the tumor's attempts to shut them down. Up to 30 participants will receive the cells in increasing doses to find the safest dose and to see if the therapy can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TmPSMA-02 CAR T cells (a patient's own immune cells modified to target prostate cancer cells and resist tumor defenses)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects from the cell therapy, and the approach may not work for most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help when standard therapy falls short for prostate cancer?
- New hope for Hard-to-Treat prostate cancer: drug combo trial launches
- New drug combo takes on tough cancers in early trial
- Real-World data reveals early use of prostate cancer drug in thousands of patients
- Immune cells armed with cancer-seeking antibodies tested in advanced cancers
- Supercharged immune cells take on Hard-to-Treat prostate cancer